CRIS Current Research Information System

DE GIOVANNI, CARLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.400
EU - Europa 2.698
AS - Asia 2.468
AF - Africa 257
SA - Sud America 150
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 6
Totale 9.987
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.341
SG - Singapore 722
GB - Regno Unito 696
CN - Cina 683
VN - Vietnam 609
IT - Italia 489
DE - Germania 342
SE - Svezia 256
HK - Hong Kong 205
RU - Federazione Russa 159
UA - Ucraina 154
IN - India 129
CH - Svizzera 127
FR - Francia 112
BR - Brasile 111
CI - Costa d'Avorio 105
IE - Irlanda 97
ZA - Sudafrica 61
NL - Olanda 57
TG - Togo 56
CA - Canada 45
EE - Estonia 43
JP - Giappone 42
BG - Bulgaria 33
BE - Belgio 31
FI - Finlandia 28
SC - Seychelles 18
AR - Argentina 17
ID - Indonesia 16
KR - Corea 16
RO - Romania 15
LT - Lituania 11
NG - Nigeria 11
PL - Polonia 11
EC - Ecuador 10
JO - Giordania 10
MX - Messico 9
ES - Italia 7
AT - Austria 6
HR - Croazia 6
TR - Turchia 6
AU - Australia 5
BD - Bangladesh 5
CL - Cile 5
GR - Grecia 5
IR - Iran 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
DK - Danimarca 4
EU - Europa 4
EG - Egitto 3
IQ - Iraq 3
A2 - ???statistics.table.value.countryCode.A2??? 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PE - Perù 2
PK - Pakistan 2
UZ - Uzbekistan 2
AM - Armenia 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
LI - Liechtenstein 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MY - Malesia 1
NR - Nauru 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
YE - Yemen 1
ZM - Zambia 1
Totale 9.987
Salva come PNG Salva come JPEG
Città #
Southend 580
Fairfield 523
Chandler 484
Singapore 471
Ashburn 466
Houston 267
Woodbridge 242
Wilmington 228
Ann Arbor 208
Hong Kong 203
Seattle 201
Dong Ket 161
Cambridge 155
Princeton 148
Santa Clara 140
Bologna 133
Ho Chi Minh City 111
Jacksonville 106
Abidjan 105
Bern 101
Dublin 97
Beijing 95
Boardman 90
Hanoi 83
Hefei 64
Dallas 62
Westminster 59
Nanjing 57
Lomé 56
Padova 54
Los Angeles 44
Tokyo 41
Berlin 39
Bremen 36
Buffalo 33
Jinan 33
Sofia 32
Brussels 31
San Diego 30
Milan 29
Redwood City 29
Saint Petersburg 28
Guangzhou 26
New York 26
Shenyang 26
Helsinki 23
Mülheim 23
Nanchang 22
Tianjin 22
Hebei 21
Changsha 19
Phoenix 19
Redmond 19
Turin 19
Falkenstein 17
London 17
Ottawa 17
Redondo Beach 17
Des Moines 16
Falls Church 16
Seoul 16
Bulle 15
Jiaxing 15
Mahé 15
Toronto 15
Jakarta 14
Shanghai 14
São Paulo 14
Amsterdam 13
Frankfurt am Main 13
Zhengzhou 13
Da Nang 11
Rome 11
Abeokuta 10
Amman 10
Bengaluru 10
Haiphong 10
Hangzhou 10
Hải Dương 10
Moscow 9
Taizhou 9
Verona 9
Yubileyny 9
Casalecchio di Reno 8
Kuban 8
Quận Bình Thạnh 8
Shijiazhuang 8
Stockholm 8
Haikou 7
Medford 7
Ningbo 7
Taiyuan 7
Warsaw 7
Bühl 6
Bắc Ninh 6
Dearborn 6
Johannesburg 6
Nuremberg 6
Paris 6
Boston 5
Totale 6.911
Salva come PNG Salva come JPEG
Nome #
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 353
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 305
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 242
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment 240
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells 223
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 221
Rethinking herpes simplex virus: the way to oncolytic agents. 214
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 213
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 197
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 193
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. 188
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 187
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 186
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 183
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins 181
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 176
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 175
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 169
Oncolytic herpes virus retargeted to HER-2. 167
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 167
In silico modeling and in vivo efficacy of cancer preventive vaccinations 166
Antimetastatic activity of a preventive cancer vaccine. 166
Herpesviruses as oncolytic agents 163
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 163
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 162
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 162
Immunoprevention and immunotherapy of mammary carcinoma 161
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 161
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 157
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 154
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 153
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 150
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. 149
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 149
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 148
New target antigens for cancer immunoprevention 147
Immunological prevention of a multigene cancer syndrome 147
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 144
The molecular basis of herpesviruses as oncolytic agents. 144
Alterations in folate-dependent one-carbon metabolism as colon cell transition from normal to cancerous 144
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 141
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 140
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 136
2011: the immune hallmarks of cancer 136
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 135
Preclinical HER-2 Vaccines: From Rodent to Human HER-2 134
APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. 134
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. 130
Molecular and cellular biology of rhabdomyosarcoma 129
Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients 129
A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice. 129
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 128
Preclinical vaccines against mammary carcinoma. 126
Vaccines and other immunological approaches for cancer immunoprevention 125
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 125
Delivery of CD44shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ mice. 121
Gene expression profiling differences between synchronous and metachronous metastases of colorectal cancer. 117
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 109
Cancer biology, what we know and what we don't know. 108
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 107
null 99
Methods of treating bone cancer 92
Immunotherapy 85
Cancer immunoprevention 64
Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts 45
Totale 10.194
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.509
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.509
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021722 0 0 0 0 0 54 34 112 126 56 36 304
2021/20221.384 144 40 105 57 124 85 42 101 52 97 310 227
2022/20231.656 203 237 91 226 105 111 43 81 203 72 136 148
2023/2024328 17 63 20 34 23 57 24 30 4 23 10 23
2024/20251.376 135 179 130 72 228 97 76 42 17 71 56 273
2025/20261.635 386 244 286 225 365 129 0 0 0 0 0 0
Totale 10.194